98%
921
2 minutes
20
In relapsing-remitting multiple sclerosis (RRMS) patients, an enlarged perivascular space, cognitive impairment, and inflammatory immune response has been associated with the glymphatic dysfunction. Therefore, we employed the diffusion tensor image analysis along the perivascular space (DTI-ALPS) to evaluate glymphatic function in RRMS patients. The study included 39 RRMS patients and 34 age- and gender-matched healthy controls (HC). We calculated the DTI-ALPS index by placing regions of interest (ROIs) in projection and association fiber areas, adjusting for any unsuitable positions following visual inspection. Lesion masks were created based on T2 FLAIR images, and then the measured diffusion coefficients along the x, y, and z axes were calculated after removing the lesion areas, and then DTI-ALPS index was calculated. The DTI-ALPS index between the RRMS and HC groups using two-sample t-test using SPSS 27.0. Additionally, we calculated DTI metrics, including fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD). Furthermore, we explored the association between the DTI-ALPS index and DTI metrics, as well as clinical variables such as disease duration and clinical disability score. The RRMS group showed a significantly lower DTI-ALPS index compared to HC group, suggesting altered water diffusivity along perivascular spaces. The DTI-ALPS index demonstrated a negative correlation with clinical disability and disease duration, with RRMS patients exhibiting decreased FA and increased MD, AD, and RD. These results suggest that changes in the DTI-ALPS index may be associated with microstructural damage and disease progression in RRMS, and may indirectly indicate impaired glymphatic function in RRMS.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neuroscience.2025.06.028 | DOI Listing |
J Neurol Neurosurg Psychiatry
September 2025
Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.
Background: Autologous haematopoietic stem cell transplantation (AHSCT) is increasingly used as a one-off disease-modifying therapy for aggressive forms of multiple sclerosis (MS). We report real-world effectiveness of AHSCT for MS in the UK.
Methods: This retrospective open-label study included patients with (pw)MS treated with AHSCT between 2002 and 2023 in 14 UK centres.
Mult Scler J Exp Transl Clin
September 2025
Department of Neurology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.
Background: In relapsing-remitting multiple sclerosis (RRMS), the assessment of clinical disease activity can be challenging.
Objectives: To determine the diagnostic potential of serum neurofilament light (sNfL) and glial fibrillary acidic protein (sGFAP) to distinguish a relapse from other causes of deterioration.
Methods: In this multicenter, prospective study, RRMS patients with new neurological symptoms in the last 14 days were followed for 12 weeks.
Brain Commun
August 2025
Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC 3004, Australia.
Patients with relapsing-remitting multiple sclerosis (RRMS) may experience disability progression independent of relapse activity (PIRA), which can be an early sign of secondary progressive MS (SPMS). We defined persistent PIRA as ongoing sustained disability over the entire available follow-up period. However, PIRA events can regress over time.
View Article and Find Full Text PDFJ Neurol
September 2025
Department of Neurology, University Medicine Essen, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Hufelandstr. 55, 45147, Essen, Germany.
Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system. The presence of other conditions alongside MS imposes a substantial personal and socioeconomic burden. In particular, the impact of comorbid autoimmune diseases (AID) on MS outcomes remains uncertain.
View Article and Find Full Text PDFBMC Neurol
September 2025
Neurology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Objective: To determine factors that contribute to delayed diagnosis and treatment of MS patients. Additionally, the study aimed to evaluate the correlation between diagnostic and therapeutic delay and disease outcome.
Methods: The current cohort observational multicenter study was performed at neurology clinics in four cities in Egypt.